Developing an End-to-End Data Management & Analysis Strategy for Biologics at AstraZeneca

Time: 10:00 am
day: Day One


  • Therapeutic potential of biologics in general, and antibodies in particular, are the most widely used biologics. Discuss recent developments in antibody design to encode more complex logic for improved therapeutics, via bispecific antibodies, T cell engagers, and antibody drug conjugates
  • Understand the complexity of biologics research and development, and the opportunity to better integrate the design-build-test-learn cycle for improved throughput and increased insight
  • Consider the potential for computational modelling and machine learning to accelerate antibody design, and the need to improve data management and experimental methods to enable this